Background External cephalic version (ECV) reduces the incidence of breech presentation at term and caesarean section for non-cephalic births. Tocolytics may improve success rates, but are time consuming, may cause side effects and have not been proven to alter caesarean section rates. The aim of this trial was to determine whether tocolysis should be used if ECV is being re-attempted after a failed attempt. Objective To determine whether tocolysis should be used if ECV is being re-attempted after a failed attempt.
INTRODUCTION
Breech presentation occurs at birth in 3 -4% of all deliveries and is a major contributor to the caesarean section rate. 1 This problem has increased 2 following the publication of the Term Breech Trial. 3 Although external cephalic version (ECV) reduces both the incidence of breech presentation at delivery and the caesarean section rate, 4 this effect is limited by low success rates, especially in white British women. 5 Tocolysis may improve success, but the effect on non-cephalic births is limited. 6 It is also time consuming and may be unpleasant, and it is not known whether it is best administered before every attempt at ECV or whether it should be used only after a failed attempt.
The aim of this trial was to test the null hypothesis that tocolysis for a repeat ECV (i.e. after a failed ECV) does not increase the success rates of ECV.
METHODS
The trial was undertaken in the breech clinic, held in the delivery ward of the John Radcliffe Hospital, Oxford. Ethical approval for the study was obtained from the Central Oxford Research Ethics Committee (C00.024) in April 2000. Women were referred to the clinic from hospital or community clinics, including those attached to other local hospitals, if they had a singleton breech presentation at 36 or more (nulliparous) or 37 or more (multiparous) weeks. Health professionals were encouraged to refer all breech presentations to the clinic for ECV before considering contraindications or counselling regarding mode of delivery.
Women were eligible for the trial if they had undergone an unsuccessful attempt at ECV (without tocolysis) for a breech presentation. They were required to have had a normal cardiotocograph following this, and no potential contraindications to the use of ritodrine (cardiac disease, pre-existing or gestational diabetes, hypertension). Women ineligible for an initial attempt at ECV were those with a pre-existing indication for caesarean section, suspected unstable lie, pre-eclampsia, recent (<4 weeks) antepartum haemorrhage, suspected fetal compromise (abdominal circumference below the third centile, with either an umbilical artery resistance index above the 97th centile or deepest amniotic fluid pocket <2 cm) or rhesus isoimmunisation.
Information sheets regarding the trial were given in advance of the initial ECV attempt. After a failed attempt on an eligible patient, written consent was obtained by the research midwife. Consenting patients were then randomly allocated, in a ratio of 1:1, to receive either tocolysis or placebo for a repeat attempt at ECV. Randomisation was achieved using random block sizes up to 20, with the allocations in sealed numbered opaque envelopes opened in sequential order on the delivery ward. Both the patient and the ECV operator were blinded to the result of randomisation, including maternal observations, and the latter was not allowed to enquire about side effects.
Tocolysis was administered as ritodrine hydrochloride (Yutopar) infusion of 50 mg (10 mg/mL) added to 12 mL dextrose saline (total 17 mL of ritodrine 3 mg/mL). This was administered by a syringe pump, starting at 1 mL/hour and increasing at 10-minute intervals to a maximum of 5 mL/hour, provided the maternal pulse did not exceed 120/minute. The placebo consisted of 17 mL dextrose saline solution by the same route and in similar increments, for a maximum of 50 minutes. Maternal pulse and blood pressure were measured every 10 minutes in both arms. ECV was re-attempted at 50 minutes or when the maternal pulse exceeded 120/minute, whichever was sooner. Wherever possible, the repeat ECV was performed by the same operator as for the first attempt.
Data were collected prospectively by the research midwife. The primary outcome was the incidence of cephalic presentation at delivery. For the power calculation, we estimated a spontaneous version rate in the control group of 5%. 7 Tocolysis for all women increases success rates from approximately 40% to 55%. 8, 9 Therefore, of the 60 women out of 100 who have had a failed attempt without tocolysis, a further 15 (25%) could reasonably be expected to have a second successful attempt with tocolysis. To detect an increase in the incidence of cephalic presentation from 5% to 25% with 90% power (a ¼ 0.05), 124 patients were required.
Secondary outcomes were the incidence of successful ECV, incidence of caesarean section, length of hospital inpatient stay, incidence of neonatal Apgar scores <7 at 5 minutes, neonatal intensive care unit admission or other rarer neonatal outcomes and mean cord arterial pH. A patient assessment of discomfort using an abbreviated, modified McGill pain intensity score 10 was also compared.
Analysis was by intention to treat. For categorical variables, relative risks were calculated, with 95% confidence intervals. Continuous variables, where normally distributed, were compared by a t test. Data were entered prospectively on a database SPSS 8.0 (Chicago, Illinois). Demographic and antenatal data were obtained retrospectively at the time of recruitment. Outcome details were collected retrospectively from hospital computerised records. ECV details were collected prospectively. The treatment allocation was recorded only as a number: randomisation details were revealed only when recruitment was complete.
The funding source had no role in the study design, data collection, analysis or interpretation or in the writing of this report.
RESULTS

Between 12 June 2000 and 11 November 2003, 505
women with a breech presentation were seen in the clinic and 124 women were recruited to the trial (Fig. 1) . Follow up was available on all women, and in all cases women underwent the treatment to which they had been allocated. Demographic variables are shown in Table 1 . The vast majority were of white British origin and over 70% were nulliparous.
An increase in cephalic presentation at delivery was found ( Table 2 ). This was due to an increase in the success of repeat ECV and was followed by a decrease in the incidence of caesarean section. This was largely due to a reduction in the incidence of elective caesarean section for breech presentation. There were no significant differences in maternal postnatal stay or in neonatal outcomes. There was no serious neonatal or maternal morbidity in the entire cohort.
Among 505 women referred to the Breech clinic during the time period, 485 (96%) were eligible for ECV and underwent it, and in 178 (36.7%) it was successful. An additional attempt at ECV using tocolysis in all eligible women with a failed ECV would therefore have increased the number of successful ECVs by 78, giving an overall success rate of 52.8%.
The effect on the success of ECV was most marked in multiparous women (Table 3) . In nulliparous women, a statistically significant effect was not seen in the success rate or incidence of cephalic presentation at delivery or caesarean section.
While there was no difference in pain scores between the groups, only one woman experienced no pain and 93 (75.8%) described the procedure as 'discomforting'. Eight women (6.5%) described it as 'horrible' or worse. This probably under-estimates maternal discomfort at ECV because those who found the initial attempt uncomfortable would be expected to have been less likely to take part in the trial.
DISCUSSION
This trial shows that where ECV has failed, tocolysis should be used for a repeat attempt. It also confirms the benefits of ECV in reducing the caesarean section rate, particularly now that vaginal breech birth is rare.
There are potential limitations of our study. Regarding the blinding, firstly, women receiving ritodrine developed increased sympathetic tone. The operator, however, did not record or see the maternal observations, and as the use of ultrasound required the room to be darkened, any facial flushing could not be seen. Secondly, we cannot prove that the operator could not deduce the allocation from the time between the initial attempt and the trial attempt because the pulse in women receiving tocolysis might reach the maximum allowed before the 50 minutes for which women allocated to the placebo arm had to wait. In practice, the person performing ECV was also covering the delivery ward and all timing was determined by the research midwife. Another criticism concerns the initial success rate, which was low when compared with some published series. This, however, is likely to be due to not using tocolysis, to the small number of contraindications to ECV and to the fact that ECV was always attempted in consenting women however difficult it might be. In addition, there was a small percentage of women in whom ECV is less difficult: multiparous women 11 and those of non-white British race. 5 Given that tocolysis is effective at improving ECV success rates, the choice is whether it should be used for all, or where an initial attempt has failed, or just for nulliparous women. This trial does not directly answer this question, but deductions can be made.
Despite evidence as to the safety of ECV, 7 concerns among women and obstetricians remain. This can result in precautions such as starvation of women, intravenous access and use of an operating theatre. We did not use any of these because we, and others, 11 have not needed to resort to emergency delivery. Therefore, the risks of emergency delivery are much lower than, say, for normal labour, when such precautions are not routine. Although the procedure does not take long, counselling and monitoring afterward may do, and considerable manpower and resources are required. 12 The time and monitoring of tocolysis and the side effects of tocolysis will increase this requirement considerably. With a policy of tocolysis only after a failed initial attempt, we would have achieved a similar overall success rate (52.8%) to other series using tocolysis for all, 8, 9 despite using it in only 63.3% of all women. This is in spite of our points about why ECV could be more difficult in our group of women. The other alternative of using tocolysis only in nulliparous women, as has been advocated by some, 9 could have led to fewer overall successes. This is because the effect of tocolysis seemed most marked in the small group of multiparous women. This influence of parity may also mean that a larger effect of tocolysis would have been evident if multiparous women had not been under-represented in the trial.
A further question concerns the choice of tocolytic. We used ritodrine because this has been clearly shown to improve overall ECV success rates 6, 13 while some others have not. It may, however, be that atosiban (Tractocile) is as effective with fewer side effects and a faster onset of action: its use should be investigated in a randomised, controlled trial.
CONCLUSIONS
External cephalic version success rates can be markedly improved, and non-cephalic births and caesarean section for breech presentation reduced, by the use of tocolysis if a second attempt is made. Restriction of its usage to this indication might lead to a higher overall success rate than when it is used simply for all nulliparous women and lead to less use of tocolysis and therefore side effects, time and resources than when it is simply used for all.
